Science news

<<  return


The results of randomized, controlled trial (Evaluation of Varenicline in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) show, that patients who were smokers and who started on  smoking-cessation drug varenicline (Chantix/Champix, Pfizer) while hospitalized for acute coronary syndromes (ACS) were significantly more likely than a control group to be smoking-abstinent 24 weeks later. The smoking-cessation intervention also included "low-intensity counseling," a mean of 46 minutes total for the entire trial.

The  results are important because clinical trials have not examined the efficacy of nicotine-replacement therapy in this patient population and because several trials of bupropion in these patients suggest that it is not efficacious.The results of  study was published  in Circulation.